Effect of High Flow Nasal Cannula Oxygenation on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients: A Multicentre Randomised Controlled Trial

What this Trial Is About

Researchers are studying the use of high flow nasal cannula oxygenation (HFNC) to reduce the risk of low oxygen levels (hypoxia) during sedated gastrointestinal endoscopy in critically ill patients with American Anesthesiologist Rating (ASA) grades 3 to 4. This study compares HFNC with regular nasal cannula oxygen in patients undergoing these procedures to better understand how HFNC might help prevent breathing problems and related complications during sedation. Participants will be randomly assigned to one of two groups: one receiving oxygen through a high flow nasal cannula device called Airvo2, delivering oxygen at 60L/min with 100% concentration during the procedure; the other group will receive oxygen via a regular nasal catheter at 6L/min. Oxygen delivery starts before anesthesia induction and continues throughout the endoscopy, which is expected to last no more than 60 minutes. The study is conducted at multiple centers and uses a single-blind design where patients do not know which oxygen method they receive. During the hospital stay, which typically lasts about two hours, researchers will monitor participants for episodes of hypoxia, severe hypoxia, and subclinical respiratory depression. They will also track sedation-related and respiratory complications to evaluate safety and effectiveness. The main outcome is the rate of hypoxia during the procedure. This trial includes adults aged 18 to 80 years undergoing elective gastroenteroscopy with a body mass index between 18 and 28 kg/m2 and ASA grades 2 to 3.

Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients